Rendu-Osler disease: treatment with oestrogen/progestagen versus octreotide.

Details

Serval ID
serval:BIB_0E8F4514F6CF
Type
Article: article from journal or magazin.
Publication sub-type
Case report (case report): feedback on an observation with a short commentary.
Collection
Publications
Institution
Title
Rendu-Osler disease: treatment with oestrogen/progestagen versus octreotide.
Journal
BMJ Case Reports
Author(s)
Jeanneret S., Regazzoni L., Favrat B.
ISSN
1757-790X (Electronic)
Publication state
Published
Issued date
2011
Volume
2011
Number
23 February
Pages
bcr1120103534
Language
english
Notes
Publication types: Case Reports ; Journal Article Publication Status: epublish
Abstract
In Rendu-Osler disease, haemorrhages due to gastrointestinal vascular malformations are common. Surgical and endoscopic treatments for haemorrhage due to gastrointestinal vascular malformations are compromised when lesions are diffuse, escape identification or are inaccessible to treatment. Hormonal treatment with oestrogen and progestagens is still controversial based on contradictory results from two randomised clinical trials. Although somatostatin and its long-acting analogue, octreotide, have been reported to be beneficial in preventing rebleeding, there is no consensus on this type of treatment. This case report shows how the combination of ethinyloestradiol and norethisterone markedly reduced the need for blood transfusions with few side effects in one patient; in comparison, octreotide seems less effective but this could be related to a worsening of the disease.
Keywords
Aged, Estrogens/therapeutic use, Humans, Male, Octreotide/therapeutic use, Progestins/therapeutic use, Telangiectasia, Hereditary Hemorrhagic/drug therapy
Pubmed
Create date
25/02/2011 18:28
Last modification date
20/08/2019 13:35
Usage data